Patents Represented by Attorney, Agent or Law Firm David M. Stemerick
  • Kinase inhibitors
    Patent number: 8318939
    Abstract: Compounds, pharmaceutical compositions, kits and methods are provided for use with kinases that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: November 27, 2012
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Qing Dong, Bheema R. Paraselli, Nicholas Scorah, Michael B. Wallace, Jeffrey A. Stafford
  • MAPK/ERK kinase inhibitors
    Patent number: 8293901
    Abstract: Compounds of the following formula are provided for use with MEK (I): wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: October 23, 2012
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Qing Dong, Nicholas Scorah, Steven W Kaldor
  • Hexahydrooxazinopterine compounds
    Patent number: 8268819
    Abstract: The present invention relates to intermediates of the formula wherein G1 is N; G2 is selected from the group consisting of C?O and CH2; X is a halogen; and the other groups are defined herein.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: September 18, 2012
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Bohan Jin, Nicholas Scorah, Qing Dong
  • Polo-like kinase inhibitors
    Patent number: 8202990
    Abstract: The present invention relates generally to processes of making 4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide and Form A of 4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide.
    Type: Grant
    Filed: September 25, 2008
    Date of Patent: June 19, 2012
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Christopher McBride, Zhe Nie
  • Hexahydrooxazinopterine compounds
    Patent number: 8163755
    Abstract: The present invention provides mTOR inhibitors of the formula wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods of making the compounds and intermediates thereof; and methods of using the compounds.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: April 24, 2012
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Bohan Jin, Nicholas Scorah, Qing Dong
  • MAPK/ERK kinase inhibitors
    Patent number: 8088783
    Abstract: Compounds of the substituted 1,3-dialkyl-2,4-dioxo-6-(pyrimidinylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acids, show below: wherein the variables are as defined herein, and pharmaceutical compositions thereof, are provided for use as inhibitors of with MEK kinase.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: January 3, 2012
    Inventors: Qing Dong, Stephen W. Kaldor
  • HSP90 inhibitors
    Patent number: 8071766
    Abstract: The invention relates to HSP90 inhibiting compounds consisting of the formula: wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: December 6, 2011
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Young K. Chen, Erick Co, Prasuna Guntupalli, John D. Lawson, Wolfgang Reinhard Ludwig Notz, Jeffrey A. Stafford, Huong-Thu Ton-Nu
  • MAPK/ERK kinase inhibitors
    Patent number: 8063066
    Abstract: Compounds are provided for use with MEK that comprise: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Grant
    Filed: March 17, 2008
    Date of Patent: November 22, 2011
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Qing Dong, Toufiko Kanounl, Michael B. Wallace
  • MAPK/ERK kinase inhibitors
    Patent number: 8030317
    Abstract: Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: October 4, 2011
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Qing Dong, Stephen W. Kaldor
  • Polo-like kinase inhibitors
    Patent number: 8026234
    Abstract: Compounds of the following formula are provided for use with kinases: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Grant
    Filed: September 24, 2008
    Date of Patent: September 27, 2011
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takashi Ichikawa, Stephen W. Kaldor
  • MAPK/ERK kinase inhibitors
    Patent number: 8022057
    Abstract: Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: September 20, 2011
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Qing Dong, Toufike Kanouni, Michael B. Wallace
  • Halo-substituted pyrimidodiazepines
    Patent number: 8003785
    Abstract: The present invention provides PLK1 inhibitor compounds of formula I: useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors and other oncological diseases such as non-Hodgkin's lymphomas. Also provided are intermediate compounds useful in the synthesis of compounds of formula I.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: August 23, 2011
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jianping Cai, Shaoqing Chen, Xin-Jie Chu, Kin-Chun Luk, Steven Gregory Mischke, Hongmao Sun, Peter Michael Wovkulich
  • MAPK/ERK kinase inhibitors
    Patent number: 7943659
    Abstract: Compounds, pharmaceutical compositions, kits and methods are provided for use with MEK that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: May 17, 2011
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Mark E. Adams, Qing Dong, Michael B. Wallace
  • Substituted 1,3-dialkyl-2,4-dioxo-6-(pyridylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase
    Patent number: 7943626
    Abstract: Compounds of the substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acids, show below: wherein the variables are as defined herein, and pharmaceutical compositions thereof, are provided for use as inhibitors of with MEK kinase.
    Type: Grant
    Filed: January 5, 2010
    Date of Patent: May 17, 2011
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Qing Dong, Stephen W. Kaldor
  • Palladium-catalyzed cross-coupling chemistry on 3-chloro-4-halo-1,2,5-thiadiazole
    Patent number: 6620940
    Abstract: The present invention relates to 3-chloro-4-halo-1,2,5-thiadiazole compounds, a method of producing novel mono- and di-substituted-1,2,5-thiadiazoles therefrom, as well as mono- and di-substituted -1,2,5-thiadiazoles.
    Type: Grant
    Filed: September 27, 2000
    Date of Patent: September 16, 2003
    Assignee: Eli Lilly and Company
    Inventor: Roger Lewis Robey
  • 7-oxo-2-azabicyclo[2.2.1]heptanes as selective muscarinic receptor antagonist
    Patent number: 6559171
    Abstract: The present invention relates to muscarinic receptor modulators, specifically, 7-oxo-2-azabicyclo[2.2.1]heptanes of formula (I) which are useful for the treatment of various diseases and conditions, for example, Alzheimer's disease, glaucoma, psychosis, particularly schizophrenia or schizophreniform conditions, mania, pain, bipolar disorder, depression, sleeping disorders, epilepsy, gastrointestinal motility disorders, urinary incontinence, and cognition enhancement.
    Type: Grant
    Filed: November 1, 2001
    Date of Patent: May 6, 2003
    Assignee: Eli Lilly and Company
    Inventors: Charles Howard Mitch, Steven James Quimby
  • Methods for preparing 3-arloxy-3-arylpropylamines and intermediates thereof
    Patent number: 6541668
    Abstract: The present invention provides processes for the preparation of 3-aryloxy-3-arylpropylamines and intermediates thereof using an nucleophilic aromatic displacement in 1,3-dimethyl-2-imidazolidinone or N-methylpyrrolidinone.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: April 1, 2003
    Assignee: Eli Lilly and Company
    Inventors: Douglas Patton Kjell, Kurt Thomas Lorenz
  • Indane derivatives for antipsychotic compositions
    Patent number: 6429317
    Abstract: The present invention provides novel indane-like compounds which can be useful for treating psychosis and other conditions associated with the modulation of a muscarinic receptor. The invention provides formulations and methods for using the novel compounds.
    Type: Grant
    Filed: September 5, 2000
    Date of Patent: August 6, 2002
    Assignee: Eli Lilly and Company
    Inventors: Sean P. Hollinshead, Michael A. Staszak, John S. Ward, Joseph W. Wilson, Bret E. Huff, Philip F. Hughes, Jose S. Mendoza, Charles H. Mitch
  • Pharmaceutical compounds
    Patent number: 6395735
    Abstract: The present invention provides novel indane-like compounds which can be useful for treating psychosis and other conditions associated with the modulation of a muscarinic receptor. The invention provides formulations and methods for using the novel compounds.
    Type: Grant
    Filed: December 19, 2000
    Date of Patent: May 28, 2002
    Assignee: Eli Lilly and Company
    Inventors: Sean Patrick Hollinshead, Philip Floyd Hughes, Jose Serafin Mendoza, Joseph Wendell Wilson, Bret Eugene Huff, Charles Howard Mitch, Michael Alexander Staszak, John Stanley Ward
  • Method for treating schizophrenia
    Patent number: 6284771
    Abstract: The present invention provides a method for treating a condition selected from the group consisting of schizophrenia, schizoaffective disorder, and schizophreniform disorder in a patient using a Compound (I).
    Type: Grant
    Filed: April 3, 2000
    Date of Patent: September 4, 2001
    Assignee: Eli Lilly and Company
    Inventors: Charles H. Mitch, Per Sauerberg, Harlan E. Shannon